Tafinlar + Mekinist

Active substance

Dabrafenib + Trametinib

Titulaire

Novartis Pharma

Status

Closed

Indication

Treatment of patients with BRAF V600 Activation Mutation-Positive advanced Non-Small Cell Lung Cancer (NSCLC)

Public documents

Approbation

Information for the patient

Informed consent

Dernière mise à jour

20/11/2018